News | Cardiovascular Ultrasound | August 07, 2019

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

Study of more than 9,000 patients finds contrast group five times less likely to need repeat exam with earlier hospital discharge

Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing

August 7, 2019 — Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for ordering an inpatient transthoracic echocardiogram (TTE). Research presented at the 30th Annual American Society of Echocardiography (ASE) Scientific Sessions shows patients who received an echocardiogram with contrast were less likely to require repeat tests and had shorter hospitalizations overall. This study shows the value of contrast (ultrasound enhancing agent/UEA) for improving clinical care and potentially decreasing healthcare costs.

Lead author Katherine C. Lee, Piedmont Heart Institute and Georgia Institute of Technology, Atlanta, said, “The appropriate use of echocardiography is one of today’s most challenging issues, having significant implications for both the quality and cost of care for patients with heart failure. An echocardiogram is the recommended first diagnostic test for heart failure and also the most common test performed for heart failure. With this retrospective analysis, we looked to analyze the relationship between contrast echocardiography and repeat echo testing among 9,115 patients who were admitted to the hospital with the diagnosis of heart failure over a four-year period. We found that patients who received a contrast echocardiogram as their first test were five times less likely to require a repeat echo and were discharged earlier from the hospital than those who did not receive contrast. This result highlights the importance of quality imaging (namely contrast echocardiography) in improving patient care, with the added benefit of generating potential cost savings to hospitals nationwide.”  

Ultrasound contrast used to enhance echocardiographic images is not the same type of contrast used in invasive catheter-based procedures such as angiography. Ultrasound contrast is comprised of tiny microbubbles and is commercially available from three different vendors in the United States. It has no renal side effects, is rapidly metabolized and is safe for use, with the only side effect being rare allergic reactions (approximately 1/10,000, comparable to other imaging contrast agents).

For more information: www.asecho.org

Related Content

News | ASE
May 5, 2022 – The American Society of Echocardiography (ASE), the largest global organization for cardiovascular ...
Home May 05, 2022
Home
News | ASE
April 21, 2022 – The American Society of Echocardiography (ASE) is pleased to announce that its membership has elected ...
Home April 21, 2022
Home
News | ASE

June 29, 2021 – The virtual exhibit hall at American Society of Echocardiography (ASE) 2021 Scientific Sessions Virtual ...

Home June 29, 2021
Home
News | ASE

August 20, 2020 – More than 350 posters featuring cutting edge research on the advances in cardiovascular ultrasound ...

Home August 20, 2020
Home
Feature | ASE

August 19, 2020 — From point-of-care ultrasound (POCUS) that has been a key technology during the COVID-19 pandemic, to ...

Home August 19, 2020
Home
Feature | ASE

More than 60 companies and organizations are displaying their latest products and services at the 2018 American Society ...

Home June 22, 2018
Home
Feature | ASE

June 26, 2017 — Here is a list of some key clinical presentations and video interviews with cardiac ultrasound thought ...

Home June 26, 2017
Home
Feature | ASE

ASE Announces Meeting Highlights for 28th Annual Scientific Sessions — The program includes learning opportunities from ...

Home June 01, 2017
Home
Videos | ASE

DAIC/ITN editor Dave Fornell shares some of the innovative new technologies on the show floor of the American Society of ...

Home June 30, 2016
Home
Subscribe Now